Latest news about Zydus Life Science
HC bars Zydus Life from launching Novartis-patented Dabrafenib drug
Zydus Life Latest Results: Branded portfolio to drive over two-thirds of revenue
Zydus Life Science
1,107.70
+3.20(+0.29%)
Company Performance:
View Company Insights1D+0.29%
1M-3.59%
6M+22.75%
1Y+11.95%
5Y+107.10%
More news about Zydus Life Science
11Aug 26
Zydus subsidiary Sentynl signs option and license deal for alvelestat
Sentynl Therapeutics, a Zydus Lifesciences subsidiary, has signed an option and license agreement with Mereo BioPharma for alvelestat, targeting Alpha-1 Antitrypsin Deficiency-Associated Lung Disease. Sentynl gains exclusive U.S. commercialization rights and global manufacturing rights, while Mereo leads global development and retains rest-of-world rights. Mereo is set to receive up to $40 million in payments until NDA filing plus royalties.
04Aug 26
Zydus Lifesciences gets USFDA nod for Indocyanine Green with 180-day CGT exclusivity
Zydus Lifesciences secured final USFDA approval for Indocyanine Green for Injection, a generic of IC-Green, with 180-day CGT exclusivity. The product, used for optical imaging in various surgeries, targets a USD 125.8 mn market. Manufactured in Gujarat, it adds to Zydus' 445 US approvals.
04Aug 26
Zydus Lifesciences to present at Emkay Confluence 2026 investor conference
Zydus Lifesciences Limited confirmed its participation in the Emkay Confluence 2026 on August 13, 2026. The notice, filed with BSE and NSE on August 4, 2026, was signed by Company Secretary Dhaval N. Soni. The event serves as a platform for investor engagement and transparency.
04Aug 26
Zydus Lifesciences to Participate in Equirus Annual India Conference 2026
Zydus Lifesciences Limited has announced its participation in the Equirus Annual India Conference 2026, scheduled for August 13, 2026. The company filed the update with both BSE and NSE to notify investors. This event serves as a key communication channel for management to discuss strategic initiatives with stakeholders.
31Jul 26
Zydus Lifesciences faces ₹108.54 million stamp duty demand
Zydus Lifesciences Limited has been directed to pay ₹108.54 million in deficient stamp duty and penalties by the Office of the Superintendent of Stamps, Gandhinagar. The demand arises from a discrepancy in the market value assessment of assets acquired from Sterling Biotech Limited.
30Jul 26
Zydus Lifesciences Q1 Results: Earnings call scheduled for Aug 11
Zydus Lifesciences Limited will announce Q1 FY27 results on August 11, 2026. Dr. Sharvil Patel will host the 4:00 PM IST webinar. Audio recordings and transcripts will be available online per SEBI regulations.
25Jul 26
Zydus Lifesciences resumes Ahmedabad operations after rain suspension
Zydus Lifesciences Limited resumed operations at its Ahmedabad facilities on July 25, 2026, after suspending them due to torrential rain and waterlogging. The precautionary halt lasted two days, and the company cited improving weather conditions as the reason for restarting activities. The disclosure was made under SEBI Listing Regulations to ensure market transparency.
20Jul 26
Zydus Life Sciences Board Meeting Scheduled on August 11 to Consider Q1 Results
Zydus Life Sciences has scheduled a board meeting on August 11 to consider its Q1 financial results. The announcement signals an important upcoming event for investors and stakeholders monitoring the company's performance. No additional financial details or agenda items have been disclosed ahead of the meeting.
12Jul 26
Zydus Lifesciences Releases Integrated Annual Report for FY2025-26: Record Revenue, Strategic Acquisitions and Innovation Milestones
Zydus Lifesciences Limited released its FY2025-26 Integrated Annual Report, reporting record consolidated revenue of ₹271.5 billion (+17% YoY), EBITDA of ₹84,751 million at a 31.2% margin, and adjusted PAT of ₹54,564 million (+15% YoY). The year was marked by transformative acquisitions including Amplitude Surgical SA (MedTech), Agenus biologics facilities (CDMO), and Comfort Click Limited (Consumer Wellness), alongside key R&D milestones including USFDA NDA filing for Saroglitazar Magnesium and USFDA approval for Zycubo for Menkes disease. The Board recommended a final dividend of ₹1/- per equity share and approved a share buyback of up to ₹11,000 million, with the Thirty First AGM scheduled for August 11, 2026.
11Jul 26
Zydus Lifesciences sets AGM on Aug 11, record date July 24
Zydus Lifesciences Limited has announced the 31st Annual General Meeting for August 11, 2026, to be held via video conferencing. Remote e-voting is available from August 8 to August 10, 2026. The record date for determining dividend entitlement for the financial year ended March 31, 2026, is fixed as July 24, 2026.
10Jul 26
Zydus reports 36% renewable energy in FY26 BRSR
Zydus Lifesciences Limited filed its Business Responsibility and Sustainability Report for FY26, revealing 36% renewable energy usage, total emissions of 2,89,737 tCO2e, and 56% sustainable sourcing. The company achieved 28% waste disposal via co-processing and maintained a gender diversity of 9%.
04Jul 26
Zydus signs MoU with Apollo Hospitals to expand access to Shield cancer test
Zydus Lifesciences Ltd signed an MoU with Apollo Hospitals to expand access to the Shield Multi-Cancer Detection test in India. The test screens for 10 common cancers via a single blood draw.
30Jun 26
Zydus Lifesciences extends Sterling Biotech API deal to Sep 30, 2026
Zydus Lifesciences has extended the deadline for acquiring Sterling Biotech's API business to September 30, 2026, due to pending conditions precedent.
27Jun 26
Zydus Lifesciences forms JV with Sunshine Healthcare Lanka for Sri Lanka manufacturing
Zydus Lifesciences has formed a 50:50 joint venture with Sunshine Healthcare Lanka to establish Zydus Sunshine Lifesciences (Private) Limited, a pharmaceutical manufacturing entity in Sri Lanka. The company will invest up to USD 5 million to subscribe to 50% of the equity, with a total project commitment of over USD 20 million. The facility, located in the Horana Export Processing Zone, aims to reduce import dependence and improve access to high-quality medicines.
21Jun 26
Zydus extinguishes 87.3 lakh shares bought back at ₹1,260
Zydus Lifesciences extinguished 87,30,158 equity shares bought back at ₹1,260 per share, reducing its equity capital to 99,75,03,832 shares. The buyback, fully subscribed and capped at ₹1,100 crore, increased promoter holding to 75.01%.
17Jun 26
Zydus completes Assertio acquisition, notes repurchase rights triggered
Zydus Lifesciences Ltd. has finalized the acquisition of Assertio Holdings, Inc. at $23.50 per share, with the merger effective June 16, 2026. Following the transaction, Assertio's common stock has been delisted from the Nasdaq Global Market. The merger triggered fundamental change provisions for Assertio's 6.50% Convertible Senior Notes due 2027, granting holders the right to repurchase notes for cash on July 17, 2026, or convert them into cash by July 16, 2026, at approximately $382.58 per $1,000 principal amount.
04Jun 26
Zydus Lifesciences receives USFDA warning letter for Baddi facility
Zydus Lifesciences received a USFDA warning letter for its Baddi facility regarding purified talc not meeting USP standards. The company confirmed operations and supplies remain unaffected.
04Jun 26
Zydus Lifesciences publishes buyback ad at ₹1,260
Zydus Lifesciences Limited has published the offer opening advertisement for its buyback of up to 87,30,158 equity shares at ₹1,260 per share for an aggregate amount of ₹1,100 crore. The offer is being conducted on a proportionate basis through the tender offer route using the stock exchange mechanism. The record date for determining eligibility is May 29, 2026, and the letter of offer was dispatched to eligible shareholders on June 2, 2026.
29May 26
Zydus Saroglitazar NDA gets US FDA Priority Review for PBC
Zydus Lifesciences announced that the US FDA granted Priority Review to its NDA for Saroglitazar to treat Primary Biliary Cholangitis. The PDUFA target action date is November 27, 2026. The EPICS-III Phase 3 trial demonstrated a statistically significant biochemical response, with 56.7% of treated patients achieving response versus 9.8% on placebo. Zydus Therapeutics plans to launch the drug in the US in Q4 of FY 27, subject to approval.
28May 26
Zydus Lifesciences transmits 10,000 shares to promoter group member
Zydus Lifesciences Limited disclosed the transmission of 10,000 equity shares from Late Jasodaben Babubhai Patel to Mr. Samar Babubhai Patel, a member of the Promoter Group. The off-market transaction was executed on May 22, 2026, and intimated to the company on May 25, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.
25May 26
Zydus joins Bank of America India Conference on June 2
Zydus Lifesciences Limited is set to participate in the Bank of America India Conference scheduled for June 2, 2026, in Mumbai. The event provides a platform for engagement with institutional investors.
21May 26
Zydus to attend 360 ONE Capital conference on May 27
Zydus Lifesciences Limited will participate in the 360 ONE Capital (B&K) 16th Annual Investor Conference - TRINITY INDIA 2026 on May 27, 2026. The company disclosed this via a regulatory filing on May 21, 2026.
21May 26
Zydus completes Rs 128.83 m investment in Torrent Urja 25
Zydus Lifesciences Limited and its subsidiaries have completed the subscription of equity shares in Torrent Urja 25 Private Limited by investing the remaining Rs. 90.18 million on May 19, 2026. This final tranche, covering Tranches 2, 3, and 4, involved 90,17,848 equity shares and brought the total investment to Rs. 128.83 million for 1,28,82,640 shares. The transaction, executed under Share Subscription and Shareholders’ Agreements, aligns with the company's ESG commitments and carbon neutrality goals.
21May 26
Zydus FY26 net profit rises 11.4%; dividend announced
Zydus Lifesciences Limited announced its audited financial results for the quarter and year ended March 31, 2026, reporting a 16.8% increase in FY26 revenue to Rs. 2,71,484 mn and an 11.4% rise in net profit to Rs. 50,400 mn. The Board recommended a dividend of Re. 1 per equity share and approved a buyback of equity shares for up to Rs. 11,000 mn at Rs. 1,150 per share. Operational highlights included a 20.2% YoY growth in Q4 EBITDA to Rs. 25,544 mn and a 110 basis points expansion in margins to 33.7%.
20May 26
Zydus Life Sets FY27 Targets: High-Teens Revenue Growth, 24%+ EBITDA Margins
Zydus Life has outlined FY27 guidance including high-teens consolidated revenue growth, EBITDA margins above 24%, and total capex of ~INR 1,500 crore, with biosimilars surpassing INR 800 crore. JPMorgan maintains a Neutral rating with a ₹1050 target, upgrading FY27 earnings by 10%, while Jefferies reiterates Buy at ₹1200, raising FY28 EPS estimates by 14% on strong pipeline and US specialty momentum.
20May 26
Zydus Re-appoints Dr. Sharvil Patel as MD for 5 Years
Zydus Lifesciences Limited's board has approved the re-appointment of Dr. Sharvil P. Patel as Managing Director for five years starting April 1, 2027, and the appointment of Mr. Kulin S. Lalbhai as an Independent Director for five years starting May 19, 2026. Both appointments require shareholder approval at the next Annual General Meeting.
20May 26
Zydus Sets July 24 Record Date for FY26 Dividend
Zydus Lifesciences has fixed July 24, 2026, as the record date to determine shareholder eligibility for a final dividend of Re. 1 per share for FY26. The dividend is subject to shareholder approval at the AGM scheduled for August 11, 2026, with payment expected around August 14. The company previously reported a consolidated net profit of INR 50,400 million for FY26.
14May 26
Zydus Worldwide DMCC to Acquire Entire Stake in Assertio Holdings for USD 166.4 Million
Zydus Lifesciences' subsidiary Zydus Worldwide DMCC has signed a definitive agreement to acquire all outstanding shares of Nasdaq-listed Assertio Holdings for approximately USD 166.4 million at USD 23.50 per share in cash. The deal strengthens Zydus's U.S. specialty oncology presence through Assertio's primary asset ROLVEDON®, which recorded USD 68.23 million in turnover in 2025, and its 170+ community oncology accounts. The transaction, expected to close in FY2026-27, will result in Assertio being delisted from Nasdaq.
14May 26
Zydus Lifesciences Independent Director Apurva S. Diwanji Ceases Post Upon Tenure Completion
Zydus Lifesciences Limited disclosed that Mr. Apurva S. Diwanji (DIN: 00032072) ceased as Director, including Independent Director, effective May 12, 2026, following completion of his tenure. The company filed the requisite disclosure with BSE and NSE on May 13, 2026, and acknowledged Mr. Diwanji's contributions, dedication, and professional expertise during his tenure.
14May 26
Zydus Lifesciences GST Appeal Order Upholds Rs. 10.12 Million Penalty
Zydus Lifesciences Limited received an Appeal Order from the Central GST Appeals Commissionerate, Chandigarh, upholding a demand of Rs. 1.71 million and penalty of Rs. 10.12 million related to a GST audit covering July 2017 to March 2021. The order, passed under section 107 of the CGST Act, 2017, alleges excess or wrongful input tax credit availed by the company. Zydus intends to file a second appeal before GSTAT and has confirmed no material financial impact on its operations.
06May 26
USFDA Inspects Zydus Lifesciences' Biologics Injectable Plant in Ahmedabad; Reports 7 Observations
The USFDA completed a GMP surveillance inspection at Zydus Lifesciences' Unit 9 Biologics Injectable facility at Zydus Biotech Park, Changodar, Ahmedabad, covering the period April 27 to May 5, 2026. The inspection concluded with seven observations, with no data integrity-related observations recorded. Zydus Lifesciences has committed to working closely with the USFDA to address the observations expeditiously.
05May 26
Zydus Lifesciences Subsidiary ZVTEC Receives CGST Demand Order of Rs. 9.00 Million for Alleged Inadmissible Input Tax Credit
Zydus VTEC Limited (ZVTEC), a wholly owned subsidiary of Zydus Lifesciences Limited, received a CGST demand and penalty order of Rs. 9.00 million each from the Deputy Commissioner of CGST & Central Excise, Ahmedabad North Commissionerate, on May 4, 2026. The order, passed under Section 74 of the CGST Act, 2017, relates to alleged inadmissible Input Tax Credit availment for the period September 2020 to March 2023. Zydus Lifesciences has stated its intention to appeal the order and confirmed there is no material financial impact on ZVTEC or the company.
02May 26
Zydus Lifesciences Completes €360,000 Acquisition of French Orthopedic Firm
Zydus Lifesciences has completed the €360,000 acquisition of French orthopedic company Aptitude Orthopedie through subsidiary Amplitude SAS. The target company, incorporated in 2016, specializes in medical equipment distribution with €364,000 turnover in FY2025. The strategic acquisition aims to internalize commercial capabilities and eliminate third-party commission fees.
02May 26
Zydus Subsidiary Completes Euro 700,000 Acquisition of French Medical Distributor
Zydus Lifesciences announced the completion of its subsidiary Amplitude SAS's acquisition of FBC Medical, a French medical equipment distributor, for Euro 700,000. The transaction involves 100% share capital acquisition of the company incorporated in 2016, which has maintained consistent turnover of around Euro 935,000. The strategic acquisition aims to internalize commercial capabilities and reduce long-term selling and distribution costs by eliminating third-party commission fees.
01May 26
Zydus Lifesciences Incorporates Wholly Owned US Subsidiary Zara Merger SUB Inc.
Zydus Lifesciences has incorporated Zara Merger SUB Inc. as a wholly owned subsidiary in the United States on April 24, 2026. The new entity is authorized to issue 1,000 common stock with a par value of USD 0.001 per share and will serve internal group restructuring purposes. The company disclosed this information under Regulation 30 of SEBI Listing Obligations.
27Apr 26
Zydus Receives DCGI Approval for Phase III Trials of Anti-Malarial Zintrodiazine
Zydus Lifesciences has secured DCGI approval to conduct two Phase III clinical trials for Zintrodiazine, a novel anti-malarial drug candidate active against drug-resistant P. falciparum and P. vivax strains. The trials will enroll 651 patients for P. falciparum and 390 patients for P. vivax malaria, evaluating efficacy through PCR-adjusted ACPR as the primary endpoint. This development builds on a 2016 collaboration with Medicines for Malaria Venture to create alternatives to artemisinin-based therapies, with over 1,80,000 malaria cases reported in India last year.
23Apr 26
Zydus Lifesciences Publishes Official Notice for 'Saksham Niveshak' Campaign
Zydus Lifesciences has published the official notice for its second 100-day 'Saksham Niveshak' campaign in Financial Express and communicated the publication to BSE and NSE. The campaign runs from April 1-July 9, 2026, targeting shareholders with unpaid dividends and encouraging KYC updates to prevent IEPF transfer.
16Apr 26
Zydus Lifesciences Receives USFDA Approval for Oncology Injectable Facility
Zydus Lifesciences has secured USFDA approval for its oncology injectable manufacturing facility in SEZ1, Ahmedabad, following a successful Pre-Approval Inspection conducted in November 2025. The approval covers the new isolator injectable line and positions the company to manufacture specialized oncology products for the US market while meeting stringent regulatory requirements.
15Apr 26
Zydus Lifesciences Subsidiary Wins GST Appeal, Rs. 1.66 Million Penalty Dropped
Zydus Lifesciences Limited announced that its subsidiary German Remedies Pharmaceuticals Private Limited has successfully appealed against a GST penalty of Rs. 1.66 million imposed for FY 2018-19. The Office of Commissioner, Central GST, Appeal Ahmedabad Commissionerate dropped the entire penalty amount related to alleged excess availment of Input Tax Credit. The company confirmed no material impact on financials or operations from this favorable outcome.
10Apr 26
Zydus Lifesciences Receives ESG Rating of 68 from ESGRAIL, Up from 66 Last Year
Zydus Lifesciences Limited disclosed receiving an ESG rating of 68 from SEBI-registered provider ESGRAIL, improving from last year's rating of 66. The rating was independently prepared without company engagement, based on publicly available information. The company made this disclosure under SEBI Regulation 30 compliance requirements, with the report received on April 9, 2026.
09Apr 26
Zydus Lifesciences Submits Q4 FY26 Compliance Certificate Under SEBI Depositories Regulations
Zydus Lifesciences Limited filed its quarterly compliance certificate under SEBI regulation 74(5) for Q4 FY26, confirming proper dematerialization procedures for equity shares. The certificate, submitted on April 8, 2026, verifies that physical certificates were mutilated and cancelled after due verification, with depositories substituted as registered owners. MUFG Intime India Private Limited, the company's RTA, confirmed all procedures were completed within prescribed timelines.
08Apr 26
Zydus Life Sciences Receives Final USFDA Approval for Dapagliflozin Tablets
Zydus Life Sciences has secured final USFDA approval for Dapagliflozin tablets in 5mg and 10mg strengths, gaining 180 days of shared generic drug exclusivity. The SGLT2 inhibitor for type 2 diabetes management will be manufactured at the company's SEZ facility in Ahmedabad and targets a substantial market with annual sales of $10.20 billion.
07Apr 26
Zydus Lifesciences Gets Relief as Rs. 41.77 Million GST Demand Dropped
Zydus Lifesciences Limited received a favorable order dated March 24, 2026, from the Adjudication Authority, Gandhinagar, GST Department, dropping a Rs. 41.77 million GST demand for FY 2019-20. The company made this disclosure voluntarily as good governance practice, clarifying it's not material under SEBI regulations. While celebrating this relief, the pharmaceutical company continues to face a separate Rs. 14.20 million GST demand covering FY 2019-20 to 2023-24, which it plans to contest through appeal.
31Mar 26
Zydus Lifesciences announces transition of Mr. Mayank Satpal from Senior Management due to organizational realignment
Zydus Lifesciences Limited announced that Mr. Mayank Satpal has transitioned from Senior Management effective March 31, 2026, due to organizational realignment. The company informed stock exchanges under Regulation 30 of SEBI Listing Regulations about this management change. Mr. Satpal will continue as part of the leadership team despite the transition from Senior Management. The change is attributed to realignment of organizational reporting structure rather than a complete departure from the company.
25Mar 26
Zydus Lifesciences Receives Rs. 3.28 Cr Tax Demand Order from Gujarat Authorities for FY 2019-20
Zydus Lifesciences Limited has received a Rs. 3.28 Cr tax demand order from the Assistant Commissioner of State Tax, Gujarat, for alleged inadmissible Input Tax Credit availment during FY 2019-20. The order was received on March 24, 2026, under section 74 of the CGST Act, 2017, and includes principal amount, interest, and penalty. The company plans to appeal the order, expressing confidence in its legal position based on past High Court and Supreme Court precedents, and expects no material financial impact on its operations.
21Mar 26
Zydus Lifesciences Launches Semaglutide Injection with Innovative Reusable Multi-Dose Pen Device
Zydus Lifesciences has officially launched its Semaglutide injection in India with DCGI approval for Type 2 Diabetes and obesity treatment. The product features an innovative reusable multi-dose pen device and will be marketed under three brand names at approximately Rs. 2,200 monthly cost, addressing India's growing diabetes and obesity health challenges.
19Mar 26
Zydus Lifesciences Launches Aerolife Mini™ Foldable Inhaler For Enhanced Drug Delivery
Zydus Lifesciences has introduced Aerolife Mini™, India's first portable and foldable spacer device for respiratory care, addressing the critical challenge of suboptimal inhaler technique that affects 94% of patients. The device features compact, ready-to-use design that enhances drug delivery to lungs and improves patient adherence through greater convenience and portability.
18Mar 26
Zydus Lifesciences Strengthens Semaglutide Market Strategy with Torrent Partnership
Zydus Lifesciences has strengthened its semaglutide injection market strategy by adding Torrent Pharma as a co-marketing partner alongside its existing Lupin collaboration. The March 18, 2026 licensing agreement with Torrent provides semi-exclusive rights to market the innovative 15 mg/3 ml formulation under the SEMBOLIC™ brand, complementing Zydus's own SEMAGLYN™, MASHEMA™, and ALTERME™ brands and Lupin's Semanext® and Livarise® products.
16Mar 26
Zydus Lifesciences: SentyNL Therapeutics Signs Deal With PRG S&T To License Molecule For Hutchinson-Gilford Progeria Syndrome
Sentynl Therapeutics Inc., a wholly-owned subsidiary of Zydus Lifesciences Limited, has entered into a strategic licensing agreement with Korean rare disease specialist PRG S&T to acquire rights to investigational drug candidate Progerinin (SLC-D011) for treating Hutchinson-Gilford Progeria Syndrome. The drug has received FDA orphan drug designation and is currently finalizing a Phase 2A clinical trial, with data expected before the end of the first half of 2026.
16Mar 26
Zydus Lifesciences' Desidustat Receives NMPA Approval for Renal Anaemia Treatment in China
Zydus Lifesciences achieved a major regulatory milestone with NMPA approval for Desidustat tablets in China for treating renal anaemia. The innovative HIF-PHI drug is exclusively licensed to China Medical System Holdings Limited and addresses substantial market opportunities with over 120 million CKD patients in China.
13Mar 26
Zydus Lifesciences Receives Final USFDA Approval for Cevimeline Hydrochloride Capsules
Zydus Lifesciences has secured final USFDA approval for Cevimeline Hydrochloride Capsules 30mg, indicated for treating dry mouth associated with Sjögren's syndrome. The product, to be manufactured at the company's SEZ-II facility in Ahmedabad, has projected annual sales of USD 26.9 million and expands Zydus' regulatory portfolio to 436 approvals.
12Mar 26
Zydus Lifesciences Launches AI-Powered Continuous Glucose Monitors Diasens™ and GlucoLive™
Zydus Lifesciences Limited launched Diasens™ and GlucoLive™, AI-powered continuous glucose monitoring devices designed for diabetic, CKD, and post-transplant patients. The devices automatically stream readings every three minutes to smartphones without manual scanning, partnering with TatvaCare's GoodFlip™ app for comprehensive digital health management. This addresses India's significant diabetes burden of over 101 million adults, moving beyond episodic monitoring to continuous, AI-enhanced glucose surveillance with remote clinician oversight.
28Feb 26
Zydus Lifesciences Receives USFDA Final Approvals for Ivermectin and Dapsone Tablets
Zydus Lifesciences Limited received final USFDA approvals on February 28, 2026, for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP in 25 mg and 100 mg strengths. The products target annual US markets worth USD 14.8 million and USD 8.4 million respectively, with manufacturing planned at Ahmedabad facilities and distribution through Viona Pharmaceuticals Inc. These approvals bring the company's total USFDA approvals to 434, with 505 ANDAs filed since FY 2003-04.
27Feb 26
Zydus Lifesciences Completes Pivotal Study for Pembrolizumab Biosimilar FYB206
Zydus Lifesciences announced successful completion of the pivotal Dahlia pharmacokinetic study for FYB206, a pembrolizumab biosimilar in-licensed from Formycon AG for U.S. and Canadian markets. The study demonstrated bioequivalence to Keytruda, completing the clinical data package and clearing the pathway for near-term USFDA BLA filing in the immuno-oncology biosimilar market.
26Feb 26
Zydus Lifesciences Announces Day 1 Semaglutide Launch with Innovative Pen Device
Zydus Lifesciences announces strategic Day 1 patent expiry launch of Semaglutide injection in India featuring innovative reusable pen delivery system. The company will market the diabetes and obesity treatment under three brands with DCGI approval, addressing India's significant health burden of 8.9 crore diabetic adults.
19Feb 26
Zydus Lifesciences Injectable Plant Passes USFDA Inspection with Zero Observations
Zydus Lifesciences Limited successfully completed a USFDA Pre Approval Inspection at its Injectable Medical Devices facility in Ahmedabad with NIL observations. The inspection was conducted from February 16-19, 2026, at the company's Unit 9 facility located at Zydus Biotech Park, Changodar. This positive regulatory outcome demonstrates compliance with USFDA manufacturing standards and was disclosed under SEBI Regulation 30 requirements.
19Feb 26
Zydus Lifesciences Receives USFDA Final Approval for Bosentan Tablets for Pediatric PAH Treatment
Zydus Lifesciences Limited has received final USFDA approval for Bosentan tablets for oral suspension, 32 mg, a generic version of Tracleer® indicated for treating Pulmonary Arterial Hypertension in children aged 3 years and older. The dual endothelin receptor antagonist targets a USD 9.3 mn annual US market and will be manufactured at the company's SEZ, Ahmedabad facility. This approval brings Zydus's total USFDA approvals to 432, with 505 ANDAs filed since FY 2003-04, strengthening its presence in the specialized pediatric pharmaceutical segment.
19Feb 26
Zydus Lifesciences Launches India's First Indigenous Aflibercept Biosimilar ANYRA™
Zydus Lifesciences Limited launched ANYRA™, India's first indigenously developed Aflibercept 2 mg biosimilar, on February 19, 2026, following an agreement with Regeneron Pharmaceuticals and Bayer. The biosimilar treats multiple retinal conditions including neovascular AMD, diabetic retinopathy, and retinal vein occlusions, addressing the needs of millions of Indian patients affected by these vision-threatening diseases. With India hosting over 100 million diabetics and millions suffering from retinal disorders, ANYRA™ enhances access to affordable anti-VEGF therapy. Zydus maintains India's largest biosimilar portfolio with more than 13 biosimilars developed and manufactured domestically.
17Feb 26
Zydus Lifesciences Launches PEPAIR™, India's First Affordable Drug-Free Respiratory Device at Rs. 990
Zydus Lifesciences has launched PEPAIR™, India's first affordable OPEP device priced at Rs. 990, targeting over 90 lakh patients with chronic respiratory conditions. The drug-free, handheld device features a patented 3-resistance system designed to improve breathing in COPD, asthma, and bronchiectasis patients. Developed in partnership with AeroDel Technology Innovations, the launch strengthens Zydus's position as a leading respiratory player in India.
15Feb 26
Zydus Lifesciences Q3FY26 Results and Earnings Call Highlight Strategic Growth
Zydus Lifesciences delivered strong Q3FY26 performance with consolidated revenue of ₹68,645 million (30.30% YoY growth) and net profit of ₹10,421 million. The company held its post-results earnings call on February 10, 2026, where management discussed strategic initiatives including the upcoming Saroglitazar USFDA filing for PBC indication, biosimilar partnerships for Pembrolizumab and Ranibizumab, and the successful launch of Zycubo for Menkes disease treatment. All key business segments showed robust growth with North America up 16%, India branded formulations up 14%, and international markets growing 38% year-on-year.
14Feb 26
Zydus Lifesciences Receives USFDA Final Approval for Ammonium Lactate Cream, 12%
Zydus Lifesciences Limited has received final USFDA approval for Ammonium Lactate Cream, 12%, a topical prescription medication for dry skin conditions including xerosis and ichthyosis vulgaris. The product will be manufactured at the company's Changodar facility and distributed by Viona Pharmaceuticals Inc. With annual US sales of USD 15 mn, this approval brings Zydus's total USFDA approvals to 430 out of 505 ANDAs filed since FY 2003-04.
12Feb 26
Zydus Lifesciences Settles US Patent Dispute with Astellas for USD 120 Million
Zydus Lifesciences Limited has settled its US patent litigation with Astellas Pharma Inc. over Myrbetriq (Mirabegron) for USD 120 million plus ongoing licensing fees until September 2027. The settlement concludes all legal disputes between the companies and allows Zydus to continue marketing its generic Mirabegron in the United States. This resolution follows the company's earlier intimation about the patent litigation dated April 17, 2025.
09Feb 26
Zydus Lifesciences Board Reviews Exchange Penalties for Technical Non-Compliance with Meeting Intimation Rules
Zydus Lifesciences Limited's board reviewed penalties of ₹11,800 each from BSE and NSE for technical non-compliance with Regulation 29 regarding board meeting intimation. The issue arose from different holiday calendar interpretations between Ahmedabad (company's location) and Mumbai (exchanges' location) for a November 6, 2025 meeting. The board acknowledged the inadvertent error, confirmed penalty payments, and committed to strengthened compliance processes.
31Jan 26
Zydus Lifesciences Announces Superannuation of Senior Vice President Corporate Affairs
Zydus Lifesciences Limited announced the superannuation of Mr. Manoj Kumar Kamra, Senior Vice President-Corporate Affairs, effective January 31, 2026. The disclosure was made under Regulation 30 of SEBI listing regulations and related circulars, with formal communication filed to BSE and NSE by Company Secretary Dhaval N. Soni.
27Jan 26
Zydus Lifesciences Schedules Board Meeting on February 9, 2026 for Q3FY26 Financial Results
Zydus Lifesciences Limited has scheduled its Board of Directors meeting for Monday, February 9, 2026, to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2025. The company has notified both BSE and NSE in compliance with SEBI Regulation 29(1), and implemented a trading window closure for Directors and Designated Persons until February 11, 2026, with trading resuming on February 12, 2026.
23Jan 26
Zydus Lifesciences USFDA Inspection at Ankleswar Plant Concludes with 3 Observations
Zydus Lifesciences Limited completed a USFDA inspection at its Unit-2 manufacturing plant in Ankleswar, Gujarat, from January 19-23, 2026. The inspection concluded with 3 observations, with no data integrity related issues identified. The company has committed to working closely with the USFDA to address the observations expeditiously and made this disclosure under SEBI Regulation 30 requirements.
20Jan 26
Zydus Lifesciences ESG Rating Improved to 84/100 by S&P Global
Zydus Lifesciences Limited announced that S&P Global has revised its Corporate Sustainability Assessment ESG Score from 83/100 to 84/100 for 2025. The company had initially received the 83/100 rating in December 2025, which has now been upgraded by one point. This improvement reflects enhanced performance in environmental, social, and governance criteria as assessed by S&P Global's sustainability evaluation framework.
15Jan 26
Zydus Lifesciences Completes Agenus Acquisition, Establishes Zylidac Bio LLC for US Biologics Manufacturing
Zydus Lifesciences Limited completed its strategic acquisition of Agenus Inc.'s biologics manufacturing facilities and equity stake on January 15, 2026, following CFIUS and regulatory approvals. The transaction establishes Zylidac Bio LLC as a US-based CDMO subsidiary operating facilities in Emeryville and Berkeley, California, while securing exclusive manufacturing rights for Agenus' Phase 3 immuno-oncology candidates and commercialization rights in India and Sri Lanka.
15Jan 26
Zydus Lifesciences Receives USFDA Final Approval for Eltrombopag Tablets
Zydus Lifesciences announced on January 15 that it secured final USFDA approval for Eltrombopag Tablets in four different strengths for treating thrombocytopenia. The approval targets a significant USD 1262.50 million US market opportunity, with manufacturing planned at the company's SEZ facility in Ahmedabad, bringing their total USFDA approvals to 429 out of 505 filed ANDAs since FY 2003-04.
13Jan 26
Zydus Lifesciences Receives FDA Approval for ZYCUBO, First Treatment for Rare Menkes Disease
Zydus Lifesciences achieved a major regulatory milestone with FDA approval of ZYCUBO for Menkes disease treatment through its US subsidiary Sentynl Therapeutics. This represents the first approved therapy for the rare genetic condition in the United States. Clinical trials showed 177.1 months median survival for early treatment versus 17.6 months for untreated patients, demonstrating nearly 80% reduction in death risk.
10Jan 26
Zydus Lifesciences Dissolves French Subsidiary Ampliman 2 Without Business Impact
Zydus Lifesciences Limited dissolved its French subsidiary Ampliman 2 effective January 9, 2026, without liquidation. All assets and liabilities were transferred to parent company Zydus MedTech (France) S.A.S. The pharmaceutical company confirmed this restructuring will not impact business operations, representing a streamlining of its European subsidiary structure.
02Jan 26
Zydus Lifesciences Dissolves Luxembourg Subsidiary Auroralux S.A.S. Effective December 31, 2025
Zydus Lifesciences has announced the dissolution of its wholly owned subsidiary Auroralux S.A.S., Luxembourg, effective December 31, 2025, without liquidation. All assets and liabilities will be transferred to Zydus MedTech (France) S.A.S., ensuring business continuity with no operational impact.
30Dec 25
Zydus Lifesciences Receives ₹2.8 Crore GST Demand Order for FY 2018-19
Zydus Lifesciences Limited received a ₹2.8 crore GST demand order from Gujarat tax authorities for alleged inadmissible Input Tax Credit availment during FY 2018-19. The order was issued under section 74 of CGST Act, 2017, and received on December 29, 2025. The company plans to appeal the decision, citing favorable precedents from higher courts, and maintains there will be no material financial impact on operations.
24Dec 25
Zydus Lifesciences Further Extends Sterling Biotech API Acquisition to June 2026
Zydus Lifesciences has announced a second extension for its Sterling Biotech API business acquisition, moving the deadline to June 30, 2026. The extension follows ongoing processes at Sterling Biotech to complete conditions precedent outlined in the Business Transfer Agreement originally signed in September 2024.
24Dec 25
Zydus Partners with Bioeq for US Biosimilar Rights to NUFYMCO
Zydus Lifesciences has formed a strategic partnership with Swiss biopharmaceutical company Bioeq AG for the commercialisation of NUFYMCO, an interchangeable biosimilar to Lucentis (Ranibizumab) in the US market. The collaboration involves Zydus handling commercialisation while Bioeq manages development, manufacturing and supply, targeting a $210 million market opportunity with FDA approval confirmed on December 18, 2025.
23Dec 25
High Court Permits Zydus Lifesciences to Manufacture and Export Semaglutide
Zydus Lifesciences has received High Court permission to manufacture semaglutide, a medication used for diabetes treatment and weight management. The court order also allows the company to export the drug to specific international markets. This regulatory approval enables Zydus to enter semaglutide production for both domestic and select international markets, potentially expanding its presence in the diabetes care and weight management sectors.
19Dec 25
Zydus Signs Exclusive Agreement with Myriad Genetics for Cancer Testing in India
Zydus Lifesciences Limited has entered into an exclusive partnership with US-based Myriad Genetics to introduce advanced cancer-risk assessment diagnostic tests in India. The agreement covers three key tests: MyRisk Hereditary Cancer Test analyzing 63 genes for hereditary cancer risk, MyChoice HRD Plus Test for ovarian cancer treatment decisions, and Prolaris Test for prostate cancer prognosis, marking a significant expansion in precision oncology services for Indian patients.
16Dec 25
Zydus Lifesciences ESG Score Improves to 69.4, Mourns Senior Executive Loss
Zydus Lifesciences has received an enhanced ESG score of 69.4 for FY25 from SES ESG Research, improving from the previous year's 67.8, maintaining its Medium Risk category. The company also announced the passing of Mr. Samir Desai, President-BU Biologics, ensuring regulatory compliance through timely disclosures to stock exchanges.
16Dec 25
Zydus Lifesciences: Sentynl Therapeutics Gets FDA Acceptance for CUTX-101 NDA
Zydus Lifesciences announced that Sentyln Therapeutics received FDA acceptance for CUTX-101 NDA resubmission targeting Menkes disease treatment, with a PDUFA date of January 14, 2026. The investigational therapy demonstrated significant clinical efficacy with 80.00% reduction in death risk and could become the first approved treatment for this rare pediatric genetic condition.
12Dec 25
Zydus Lifesciences Secures 99.89% Shareholder Approval for ₹5,000 Crore Fundraising
Zydus Lifesciences achieved a decisive 99.89% shareholder approval for its ₹5,000 crore fundraising initiative through postal ballot voting conducted on December 12, 2025. The approved framework allows flexible fund raising through various instruments including equity shares, convertible securities, and debentures via methods like QIP, rights issue, and preferential allotment. Additionally, the company received its first NMPA approval in China for Venlafaxine ER Capsules, marking a significant milestone in its international expansion strategy.
12Dec 25
Zydus Life Sciences Announces Postal Ballot Voting Results for Special Resolution
Zydus Life Sciences Limited completed its postal ballot voting process for a special resolution on December 12, 2025, with remote e-voting conducted through CDSL from November 13 to December 12, 2025. The company reported voting results across different shareholder categories and submitted compliance documents to BSE and NSE under SEBI Listing Regulations.
10Dec 25
Zydus Lifesciences Launches Bone Health Drug Zyrifa For Cancer Patients At ₹12,495
Zydus Lifesciences has launched Zyrifa, a specialized bone health medication priced at ₹12,495 designed to prevent skeletal complications in cancer patients. The launch strengthens the company's oncology portfolio and demonstrates its commitment to addressing critical healthcare needs in cancer treatment.
10Dec 25
Zydus Lifesciences Partners with Formycon for Exclusive Biosimilar Keytruda Deal in North America
Zydus Lifesciences has formed an exclusive partnership with Formycon for licensing and supply of a biosimilar to Keytruda in the US and Canada. This strategic collaboration strengthens the company's biosimilar portfolio and expands its presence in key North American pharmaceutical markets. The partnership provides exclusive access to advanced biosimilar technology for one of the most significant oncology treatments.
04Dec 25
Zydus Lifesciences' Jarod Injectable Facility Receives USFDA Inspection Report
Zydus Lifesciences' Jarod Injectable Facility has received a 'Voluntary Action Indicated' (VAI) classification from the USFDA following a Good Manufacturing Practices inspection. The VAI status indicates minor deficiencies that require attention but allows continued operations. Zydus is expected to address these concerns voluntarily, demonstrating its commitment to maintaining high-quality manufacturing standards.
25Nov 25
Zydus Lifesciences Secures USFDA Approval for Cardiac Medication
Zydus Lifesciences has obtained final approval from the U.S. FDA for its Verapamil Hydrochloride Extended-Release Tablets, a medication used to treat cardiac conditions. This approval allows Zydus to market and distribute the product in the United States, expanding its product portfolio and strengthening its position in the U.S. pharmaceutical market. Verapamil Hydrochloride is a calcium channel blocker used for treating high blood pressure, chest pain, and certain heart rhythm disorders.
19Nov 25
Zydus Foundation Loses Wholly-Owned Subsidiary Status Following Share Allotment
Zydus Life Science announced that its wholly-owned subsidiary, Zydus Foundation, has ceased to hold that status following a preferential share allotment. On November 19, 2025, Zydus Foundation issued 4,50,000 equity shares to Ramanbhai Foundation, a public charitable trust. Zydus Life Science now retains 50,000 equity shares in Zydus Foundation. The transaction was conducted at fair value, determined by a SEBI-registered valuer, and on an arm's length basis. The financial impact on Zydus Life Science appears minimal, with no contribution to income or net worth for the fiscal year ending March 31, 2025.
14Nov 25
Zydus Lifesciences Expands Oncology Portfolio with FDA Approval for Prostate Cancer Drug
Zydus Life Science has obtained final USFDA approval for Leuprolide Acetate Injection, used in the palliative treatment of advanced prostatic cancer. The drug, with estimated annual U.S. sales of $69.00 million, will be manufactured at Zydus' oncology injectable facility in Ahmedabad. This approval marks Zydus' 427th USFDA approval, strengthening its oncology portfolio and U.S. market presence.
14Nov 25
Zydus Lifesciences: CE Mark for Surgical Robot, USFDA Approval for MS Drug, and FDA Inspection of Oncology Facility
Zydus Life Science has received CE mark approval for its robotic surgical system 'Andy', USFDA approval for Diroximel Fumarate Delayed-Release Capsules to treat multiple sclerosis, and completed a US FDA inspection at its oncology injectable facility. The 'Andy' system combines navigation technology with robotic assistance for orthopaedic surgeries. The multiple sclerosis treatment has expected annual sales of $999.40 million in the US. The FDA inspection resulted in two observations with no data integrity issues.
13Nov 25
Zydus Lifesciences Reports Robust Q2 FY26 Performance with 17% Revenue Growth
Zydus Life Science reported robust Q2 FY26 results with consolidated revenues of Rs 61.20 billion, up 17% year-on-year. EBITDA margin improved to 32.90%, with EBITDA and net profit both up 38%. US formulations business grew 14%, India branded formulations increased 9%, international markets surged 39%, and consumer wellness rose 31%. Key developments include specialty portfolio expansion, international acquisition of Comfort Click Limited, launch of India's first trivalent influenza vaccine, positive clinical trial results for Saroglitazar Magnesium, and acquisition of Amplitude Surgical.
11Nov 25
Zydus Lifesciences Secures Maiden NMPA Approval in China for Antidepressant Medication
Zydus Lifesciences has received approval from China's National Medical Products Administration (NMPA) for Venlafaxine Extended-Release Capsules in 75mg and 150mg strengths. This marks the company's first entry into the Chinese pharmaceutical market through the NMPA regulatory pathway. Venlafaxine, an antidepressant in the serotonin-norepinephrine reuptake inhibitor (SNRI) class, is used to treat major depressive disorder and anxiety disorders. The approval opens up opportunities for Zydus in one of the world's largest healthcare markets, potentially strengthening its global position.
07Nov 25
Zydus Lifesciences Reports Strong Q2 FY26 Performance, Maintains FY26 Growth Targets and Receives Tentative USFDA Approval for Olaparib Tablets
Zydus Life Science reported robust Q2 FY26 results with revenue up 17% to ₹61,232 million and net profit up 38% to ₹12,586 million. The company saw growth across all segments, with US Formulations up 13.5%, India Formulations up 8.4%, Consumer Wellness up 30.7%, and International Markets up 39.4%. Zydus completed acquisitions of Amplitude Surgical SA and Comfort Click Limited, expanding its medical devices and wellness portfolios. The company also received tentative USFDA approval for Olaparib tablets and reported positive results for Saroglitazar Magnesium in PBC trials.
06Nov 25
Zydus Lifesciences Reports Growth in US Formulations and Advances in Beta-Thalassemia Treatment
Zydus Life Science announced a 13.5% growth in its US formulations business. The company's novel oral treatment, Desidustat, received Orphan Drug Designation from the FDA for beta-thalassemia treatment. This designation offers potential benefits including market exclusivity, financial incentives, and development support. Desidustat, a HIF-prolyl hydroxylase inhibitor, shows promise in increasing hemoglobin and red blood cell counts, potentially improving life quality for beta-thalassemia patients.
06Nov 25
Zydus Lifesciences Reports Strong Q2 Growth with 38% EBITDA Jump and Board Approves ₹5,000 Crore Fundraising Plan
Zydus Lifesciences reported impressive Q2 financial results with revenue increasing 16.41% YoY to ₹6,100.00 crore. EBITDA grew 38.01% to ₹2,015.00 crore, and EBITDA margin expanded by 5.01 percentage points to 32.92%. The company's board has approved a fundraising plan of up to ₹5,000.00 crores through various securities, subject to approvals.
05Nov 25
Zydus Life Sciences Secures FDA Approval for Ahmedabad Manufacturing Facility
Zydus Life Sciences' SEZ-II manufacturing facility in Ahmedabad successfully passed a U.S. FDA Pre-Approval Inspection from August 11-14, 2025, receiving zero observations and a 'No Action Indicated' (NAI) classification. The company also received tentative USFDA approval for Budesonide delayed-release capsules on November 4, 2025. As of September 30, 2025, Zydus has 425 ANDA approvals and has filed 487 ANDAs since FY 2003-04.
01Nov 25
Zydus Lifesciences Faces ₹74.23 Crore IGST Demand, Plans to Appeal
Zydus Lifesciences has received a tax demand of ₹74.23 crores from Indian authorities for alleged excess IGST refund claims on exports from April 2018 to March 2024. The order, issued by the Joint Commissioner of Common Adjudication Authority CGST in Ahmedabad, Gujarat, covers four GST registrations across different states. The company plans to challenge the order, stating it has no material financial impact. The dispute centers on the use of CIF value instead of FOB value for export calculations.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
CiplaZydus Life Science
Lupin
Laurus Labs
Mankind Pharma
Dr Reddys Laboratories
Aurobindo Pharma
1,904.00
(+0.21%)
8,570.00
(+0.12%)
5,005.00
(-0.16%)
1,438.00
(+1.13%)
1,107.70
(+0.29%)
2,201.50
(-1.06%)
1,825.00
(+1.29%)
2,385.00
(-0.38%)
1,180.00
(+0.85%)
1,608.00
(-1.02%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
